$CRVS News
Last published 2d ago
- 2d agoCRVSCorvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswire
- 2d agoCRVSCorvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct
- 6d agoCRVSCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results - CORVUS PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon everyone and thank you for standing by. Welcome to the Corvus Pharmaceuticals 3rd Quarter 2026 Business Update and Financial Results Conference Call. At this time, all participants are in a listen-only mod
- 6d agoCRVSCorvus Pharmaceuticals, Inc. - PRESS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoCRVSCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswireEnrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Angel Pharmaceuticals completes enrollment in cohort 1 of Phase 1b/2
- 1w agoCRVSCorvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & ExpositionGlobeNewswireData shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Safety
- 1w agoCRVSCorvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and
- 2mo agoCRVSCorvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct
- 2mo agoCRVSCorvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma TrialGlobeNewswireData supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma Data in T cell lymphoma demonstrated anti-tumor activity
- 3mo agoCRVSCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results - CORVUS PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, everyone, and thank you for standing by. Welcome to the Corvus Pharmaceuticals' second quarter 2026 Business Update and Financial Results Conference Call. At this time, all participants are in listen-only
- 3mo agoCRVSCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results - CORVUS PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, everyone, and thank you for standing by. Welcome to the Corvus Pharmaceuticals' second quarter 2026 Business Update and Financial Results Conference Call. At this time, all participants are in listen-only
- 3mo agoCRVSCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial ResultsGlobeNewswireEnrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib’s potential in atopic dermatitis and broader immunology
- 3mo agoCRVSCorvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and
- 5mo agoCRVSCorvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in ChinaGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13.5 million
- 5mo agoCRVSCORVUS PHARMACEUTICALS, INC. at JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - CORVUS PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, everyone. My name is Richard Miller, and I'm the CEO of Corvus Pharmaceuticals. Welcome to you all. I'm delighted to be able to give you an update on CorvUS PharmaceuticalS. In particular, I'm going to be
- 5mo agoCRVSCorvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct
- 6mo agoCRVSCorvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual MeetingGlobeNewswireNew immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to
- 6mo agoCRVSCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial ResultsGlobeNewswireSoquelitinib clinical development for atopic dermatitis advancing with Phase 1 cohort 4 positive data and initiation of Phase 2 trial during the quarter New immunologic and biomarker data supporting the potential for
- 6mo agoCRVSCorvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been
- 6mo agoCRVSCorvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual MeetingGlobeNewswireTwo oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free remissions Investor
- 8mo agoCRVSCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireAnnounced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib
- 8mo agoCRVSCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and
- 8mo agoCRVSCorvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct
- 9mo agoCRVSCorvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201MGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public
- 9mo agoCRVSCorvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public
- 9mo agoCRVSCorvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public
- 9mo agoCRVSCorvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and webcast on
- 10mo agoCRVSCorvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of
- 11mo agoCRVSCorvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma TrialGlobeNewswirePatients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3
- 1y agoCRVSCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswireCompleted enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic dermatitis phase 2
- 1y agoCRVSCorvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & ExpositionGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of
- 1y agoCRVSCorvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct
- 1y agoCRVSCorvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and
- 1y agoONCZLABCRVSDNA+2The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive PartnersPR NewswireThe Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of...
- 1y agoCRVSCorvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025GlobeNewswireTrial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with
- 1y agoCRVSCorvus Pharmaceuticals Appoints David Moore to Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US
- 1y agoCRVSCorvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCRVSCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial ResultsGlobeNewswireSoquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8
- 1y agoCRVSCorvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and
- 1y agoCRVSCorvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic DermatitisGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner
- 1y agoCRVSCorvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 CongressGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting the potential of
- 1y agoCRVSCorvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisGlobeNewswireCohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates
- 1y agoCRVSCorvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct
- 1y agoCRVSCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial ResultsGlobeNewswireSoquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3
- 1y agoCRVSCorvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisGlobeNewswireData continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for
- 1y agoCRVSCorvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025GlobeNewswireData from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update
- 1y agoCRVSCorvus Pharmaceuticals Appoints Richard A. van den Broek to Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at
- 1y agoCRVSCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireSoquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and Novel Mechanism of
- 1y agoCRVSCorvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell LymphomaGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from the Company's Phase 1/1b
- 1y agoCRVSCorvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct